Hospitals to get state-of-the-art radiotherapy machines, ministers announce
A £70 million Government investment will see linear accelerator (Linac) machines rolled out at hospitals across the nation from August.
In the North West, The Christie in Manchester, the Clatterbridge Centre on Merseyside, and the Lancashire Teaching Hospitals NHS Trust are to receive machines.
Health Secretary Wes Streeting said the new technology would 'free up capacity so that thousands more patients are treated on time'.
The Linac machines are being prioritised in hospitals where existing machinery is over a decade old.
The latest technology is safer for patients than older radiotherapy machines, and can more closely target tumours and cause less damage to health tissue.
The machines are particularly effective with harder to reach areas of the body, like the chest and pelvis.
The Department for Health and Social Care claims the new Linac machines could reduce the number of hospital visits patients have to make for radiotherapy treatment.
It says that by March 2027, up to 27,500 additional treatments per year will be delivered, including up to 4,500 receiving their first treatment for cancer within 62-days of referral.
Mr Streeting said: 'There is a revolution taking place in medical technology which can transform treatment for cancer patients.
'But NHS hospitals are forced to use outdated, malfunctioning equipment thanks to 14 years of under-investment under the previous government.
'Thanks to the investment this Government is making in our NHS, we will provide more cancer patients with world-class, cutting-edge care.'
He added: 'By reducing the number of hospital visits required and preventing cancelled appointments, these state-of-the-art radiotherapy machines free up capacity so that thousands more patients are treated on time.
'As a cancer survivor, I know just how important timely treatment is.
'These machines are part of the investment and modernisation that will cut waiting times for patients, through our plan for change.'
NHS national clinical director for cancer Professor Peter Johnson said: 'Radiotherapy is essential for many cancer patients, so it's great news that the investment in new machines means that some will need fewer rounds of treatment, as we bring in more sophisticated techniques.
'These machines will deliver more precise treatment for patients, which helps them to recover sooner, as well as enabling the NHS to treat people more efficiently as we continue in our efforts to catch and treat more cancers faster.'
Charity Macmillan Cancer described the announcement as an 'exciting step forward for cancer treatment in England'.
Kate Seymour, head of external affairs at the charity, added: 'Many people across the country are facing long delays for care but today proves that better is possible.
'Investment in cutting-edge technology is essential to bring down waiting times and help more people with cancer get the best care the UK has to offer, whoever and wherever they are.'
Shadow health secretary Edward Argar said: 'This capital investment in new radiotherapy machines should be welcomed by everyone.
'It builds on previous investment in diagnostics by the previous Conservative government, with upgrades to provide more state-of-the-art new CT and MRI scanners.
"Today's announcement mirrors this in treatments, with new equipment to improve access to radiotherapy after diagnosis.
'But ensuring an early diagnosis remains key to tackling cancer, being able to access the treatment these machines can provide, and to getting better outcomes for patients, so alongside investment in new kit, it is vital the Government reinstates the early cancer diagnosis targets they dropped recently.'
The 28 hospital trusts receiving an upgraded scanner are:
Mid and South Essex NHS Foundation Trust
Sheffield Teaching Hospitals NHS Foundation Trust
Northampton General Hospital NHS Trust
United Lincolnshire Hospitals NHS Trust
University Hospitals Plymouth NHS Trust
Royal Free London NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
Hampshire Hospitals NHS Foundation Trust
The Royal Marsden NHS Foundation Trust
Worcestershire Acute Hospitals NHS Trust
Lancashire Teaching Hospitals NHS Foundation Trust
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
East Suffolk and North Essex NHS Foundation Trust
Royal Berkshire NHS Foundation Trust
Imperial College Healthcare NHS Trust
Maidstone and Tunbridge Wells NHS Trust
University Hospitals Bristol and Weston NHS Foundation Trust
South Tees Hospitals NHS Foundation Trust
The Christie NHS Foundation Trust
Gloucestershire Hospitals NHS Foundation Trust
Nottingham University Hospitals NHS Trust
Royal Cornwall Hospitals NHS Trust
The Clatterbridge Cancer Centre NHS Foundation Trust
University Hospitals of Derby and Burton NHS Foundation Trust
Guy's and St Thomas' NHS Foundation Trust
University College London Hospitals NHS Foundation Trust
Barts Health NHS Trust
Royal Surrey NHS Foundation Trust
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Spectator
17 minutes ago
- Spectator
Why your weight loss jab is ballooning in price
'A friend of mine who's slightly overweight, to put it mildly, went to a drug store in London,' Donald Trump said aboard Air Force One. Earlier he had told reporters: 'He was able to get one of the fat shots. 'I just paid $88 and in New York I paid $1,300. What the hell is going on? It's the same box, made in the same plant, by the same company.'' You can see why the dealmaker-in-chief was irked. And when Trump is irked, someone usually pays the price. In May, the President signed an executive order for 'most-favoured-nation prescription drug pricing for American patients'. It was a warning to drug companies, as well as other countries, that Americans were tired of paying nearly three times more for the same medicines as patients abroad. The US is home to less than 5 per cent of the world's population and yet American consumers account for almost three-quarters of global pharmaceutical profits, because manufacturers heavily discount their drugs overseas and make up the difference by inflating prices in the States. As the President puts it, 'freeloading' foreign customers 'get a free ride'. He's not wrong. But while Trump may get his wish in stopping overseas health systems from getting cheaper deals, it's not obvious that profit–making companies will cut their prices in America. The more likely response is that they'll raise them everywhere else. Eli Lilly, the American pharmaceutical giant behind the weight-loss jab Mounjaro, has announced that from September the recommended retail price of its strongest monthly dose in Britain will leap from £122 to £330 – inflation of more than 170 per cent. The company knows the NHS won't actually pay that much: it has already negotiated substantial discounts for the doses it prescribes. But by hiking the list price on the highest dose (which relatively few patients use), while cutting the private deals on lower doses, Lilly can appease Washington and protect its market at the same time. For now, anyway. But demand is picking up. In Britain, around 1.5 million people are already on weight-loss drugs, with 90 per cent paying out of pocket. Most take Mounjaro, while a smaller number are on Wegovy, the sister drug to Ozempic. Novo Nordisk, the Danish manufacturer of Wegovy, has agreed to keep its UK price low for the time being. But costs will eventually be driven up for Wegovy users too if Mounjaro users, faced with a much bigger bill, convert to Wegovy en masse, squeezing supply. Fat loss clinics are already seeing a 500 to 600 per cent increase in Brits switching to Wegovy, which – come September – will cost half the price of Mounjaro. Trump's war on drug pricing will affect other areas of British medicine too. Weight-loss jabs have become the symbol of American pharma – and its many excesses – but they are by no means the only miracle drug we get for cheap. Take Casgevy, a US-made gene therapy that can treat the blood conditions beta thalassemia and sickle cell disease. One dose costs more than £1.6 million at list price. Thanks to its clout as the country's single dominant buyer, the NHS has secured a confidential – though significant – discount. Casgevy's eye-watering price is easy to justify: therapies at the frontier of medicine cost billions to develop. British politicians love to remind us that the UK is a world leader in life sciences, and in many ways that's true, but it's the US that is funding nearly half of all global life-sciences research and development. Trump, in typical fashion, wants the credit – or at least cheaper price tags. But drug makers won't cut their profits; they'll shrink everyone else's discounts. The NHS's bargaining power may shield patients for a time, but price rises are coming. UK officials know it, too. Even before the latest hikes on the fat jabs, government papers released alongside the US-UK trade talks in May noted that the NHS would look at the concerns of the President. No prime minister or health secretary could openly sign up to higher drug costs borne by the NHS, but they knew Trump had not finished going after what he considers to be unfair trade practice. The uncomfortable truth for the British is that as much as we mock US healthcare as extortionate and venerate our NHS as sacred, we live off America's excess. The American healthcare system is Britain's greatest scapegoat: it's absurdly expensive, highly inefficient and still doesn't manage to provide universal coverage. Indeed, it's the only healthcare system in the developed world that can distract from just how poor our own is: a 'National Health Service' that falls short of practically every standard and target set for it. The NHS survives only because we ignore its outcomes. Measure after measure shows that plenty of people are being failed by an expensive, yet decaying system. Britain spends around £36 billion a year on pharmaceuticals, £19 billion of that coming from the NHS. Medicines are already the health service's second-biggest expense after staff. But that number would be a lot higher without America. Britain may be world-class in medical research, but we spend just 0.3 per cent of GDP on drug research and development, compared with America's 0.8 per cent. American money makes Britain's drug research possible. And for years, until drugs lose their patent, Americans pay exorbitant costs which subsidise the NHS's bargain prices. This model which so annoys Trump perhaps helps explain why the NHS continues to enjoy such widespread public support, despite its many failures. We'll tolerate months-long waiting lists, worse survival chances and outdated facilities if we have cheap or 'free' access to life-changing medicines. But will we put up with the broken system if we have to start paying a fair whack for drugs, either directly at the pharmacy counter or indirectly through the increased taxation that would be needed to fund them? The government won't give up our bargain pricing without a fight. Quietly, and at significant political cost, health officials will roll out a new strategy. We're never going to pay American prices for drugs – the 'free at the point of use' funding model simply could not afford it. Instead, we'll try to make our research environment so attractive to manufacturers that they'll reward us by maintaining drug discounts. That's the real motivation behind Wes Streeting's planned reforms for the NHS, which are championed by his supporters as a way to improve the patient experience and attacked by his critics as a covert means of privatising the health service. Take the single patient record, which NHS England says will give 'every part of the NHS a full picture of the patient'. Perhaps – but it will also make it far easier to identify people for clinical trials and medical research. Look at the partnership between the Wellcome Trust and the government to create a £600 million health data research service. The stated aim is to 'simplify access to health data and speed up research'. But it also makes Britain an attractive place for pharmaceutical companies. The offer is simple: we'll make it as easy and welcoming as possible for you to do your research here, you've just got to keep paying for it. This is the part British politicians never want to say out loud, especially when it comes to healthcare: someone, somewhere, is always paying for it. Drugs aren't 'cheap'. The NHS isn't 'free'. There are always trade-offs: either higher prices, longer wait times, or uncomfortable deals and data swaps with Big Medicine. No matter how you spin it, Britain's 'free ride' is coming to an end.
Telegraph
37 minutes ago
- Telegraph
NHS rolls out bladder cancer treatment that can double life expectancy
A new treatment for advanced bladder cancer that doubles life expectancy is set for use on the NHS. Experts said it was the most significant advancement in bladder cancer treatment since the 1980s. Patients diagnosed with stage four bladder cancer, which accounts for one in 10 cases, will be offered a combination of an antibody drug called enfortumab, and pembrolizumab, an immunotherapy drug. In trials, patients lived for an average of almost three years compared to 16 months in those who received standard, platinum-based chemotherapy. Experts said there had been real 'unmet need' for patients with advanced cancer, which has spread to other parts of the body, with just 29 per cent of those diagnosed with stage four living for a year. It is estimated that 1,250 people a year could benefit from the treatment. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that this doubled for those on the new treatment from just six months to more than a year. Almost a third also had a so-called 'complete response' which meant there was no detectable trace of the cancer, compared to 14.5 per cent who received chemotherapy. 'A highly promising and effective new drug' Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year. Now, three and a half years later, here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' Following approval from the National Institute for Health and Care Excellence (Nice), the treatment combination will be available for NHS patients in England diagnosed with advanced bladder cancer, who would have been eligible for the platinum-containing chemotherapy. The combination of drugs are given via an IV infusion in hospitals or clinics. Helen Knight, the director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' 'One of the most hopeful advances in decades' Prof Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, the chief executive of the charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
The Independent
an hour ago
- The Independent
First new NHS bladder cancer treatment for decades approved
A new combination treatment for advanced bladder cancer has been approved for NHS use in England. The treatment, combining enfortumab vedotin and pembrolizumab, marks the first significant advance in care for this condition since the 1980s. Clinical trials showed the new therapy doubles patients' average survival time to 33.8 months, compared to 15.9 months with chemotherapy. Approximately 1,250 people in England each year are estimated to benefit from this treatment, which also improves progression-free survival and complete response rates. Experts and patient advocates have welcomed the approval, highlighting its potential to fundamentally reshape care and significantly improve the lives of those affected.
